Advertisement

How to Induce Arrhythmias with Atropine

  • Calin Siliste
  • Roxana-Nicoleta Siliste
Chapter

Abstract

Atropine sulfate is the sulfate salt of atropine, which is an alkaloid found in its natural form together with scopolamine and hyoscyamine in the plant Atropa belladonna. The first synthesis of atropine was achieved by Richard Willstätter, a German organic chemist whose studies in the field of alkaloids brought him the 1915 Nobel Prize for Chemistry. Usual doses of atropine (>0.5 mg) abolish various types of vagal reflexmediated bradycardia or asystole and also prevent or abolish the negative chronotropic effect produced by other parasympathomimetic drugs. Atropine also ameliorates the AV conduction when an incomplete block is noted. In some patients with complete heart block, the resultant escape rhythm rate (junctional origin) may be accelerated by atropine.

References

  1. 1.
    Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 1. Am Heart J. 1980;100:255–61.CrossRefGoogle Scholar
  2. 2.
    Robinson GC, Draper G. Rhythmic changes in the human heart. Heart. 1912;4:97–106.Google Scholar
  3. 3.
    Wilson FN. The production of atrioventricular rhythm in man after the administration of atropine. Arch Intern Med. 1915;16:989–98.CrossRefGoogle Scholar
  4. 4.
    Thomas M, Woodgate D. The effect of atropine on bradycardia and hypotension in acute myocardial infarction. Br Heart J. 1966;28:409–13.CrossRefGoogle Scholar
  5. 5.
    Harris A, Bluest R. Treatment of slow heart rate following acute myocardial infarction. Br Heart J. 1966;28:631–7.CrossRefGoogle Scholar
  6. 6.
    Adgey AAJ, Geddes JA, Mulholland HC, Keegan DAJ, Pantridge JF. Incidence, significance and management of early bradyarrhythmias complicating acute myocardial infarction. Lancet. 1968;23:1097–101.CrossRefGoogle Scholar
  7. 7.
    Shillingford J, Thomas M. Treatment of bradycardia and hypotension syndrome in patients with acute myocardial infarction. Am Heart J. 1968;75:843–4.CrossRefGoogle Scholar
  8. 8.
    Harvey RD, Belevych AE. Muscarinic regulation of cardiac ion channels. Br J Pharmacol. 2003;139:1074–84.CrossRefGoogle Scholar
  9. 9.
    Montano N, Cogliati C, Porta A, Pagani M, Malliani A, Narkiewicz K, et al. Central vagotonic effects of atropine modulate spectral oscillations of sympathetic nerve activity. Circulation. 1998;98:1394–9.CrossRefGoogle Scholar
  10. 10.
    Hinderling PH, Gundert-Remy U, Schmidlin O, Heinzel G. Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: pharmacodynamics. J Pharm Sci. 1985;74:711–7.CrossRefGoogle Scholar
  11. 11.
    Adams RG, Verma P, Jackson AJ, Miller RL. Plasma pharmacokinetics of intravenously administered atropine in normal human subjects. J Clin Pharmacol. 1982;22:477–81.CrossRefGoogle Scholar
  12. 12.
  13. 13.
    Van der Meer MJ, Hundt HK, Müller FO. The metabolism of atropine in man. J Pharm Pharmacol. 1986;38:781–4.CrossRefGoogle Scholar
  14. 14.
    Kahn G. Cardiac drug therapy. 7th ed. Totowa: Humana Press; 2007. p. 198.Google Scholar
  15. 15.
    Josephson ME. Sinus node function. In: Josephson ME, editor. Clinical cardiac electrophysiology. Philadelphia: Wolters Kluwer/Lippincott Williams &Wilkins; 2008. p. 71.Google Scholar
  16. 16.
    Craig FN. Effects of atropine, work and heat on heart rate and sweat production in man. J Appl Physiol. 1952;4:826–33.CrossRefGoogle Scholar
  17. 17.
    Mandel WJ, Hayakawa H, Allen HN, Danzig R, Kermaier AI. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation. 1972;46:761–9.CrossRefGoogle Scholar
  18. 18.
    Mandel WJ, Laks MM, Obayashi K. Sinus node function; evaluation in patients with and without sinus node disease. Arch Intern Med. 1975;135:388–94.CrossRefGoogle Scholar
  19. 19.
    Morton HJV, Thomas ET. Effect of atropine on heart rate. Lancet. 1958;2:1313.CrossRefGoogle Scholar
  20. 20.
    Reiffel JA, Bigger JT, Giardina EG. “Paradoxical” prolongation of sinus nodal recovery time after atropine in the sick sinus syndrome. Am J Cardiol. 1975;36:98–104.CrossRefGoogle Scholar
  21. 21.
    Dhingra RC, Amat-Y-Leon F, Wyndham C, Denes P, Wu D, Miller RH, et al. Electrophysiologic effects of atropine on sinus node and atrium in patients with sinus nodal dysfunction. Am J Cardiol. 1976;38:848–55.CrossRefGoogle Scholar
  22. 22.
    Opthof T. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res. 2000;1(45):173–6.Google Scholar
  23. 23.
    Sethi KK, Balachandar J, Jaishankar S, Gupta MP. Differential effects of autonomic blockade on sinus and supraventricular tachycardia and dual atrioventricular atrioventricular nodal function in normals and in intrinsic sinus node dysfunction. Int J Cardiol. 1986;12:233–42.CrossRefGoogle Scholar
  24. 24.
    Bissett JK, de Soyza ND, Kane JJ, Murphy ML. Electrophysiology of atropine. Cardiovasc Res. 1975;9:73–80.CrossRefGoogle Scholar
  25. 25.
    Neuss H, Schlepper M, Spies HF. Effects of heart rate and atropine on ‘dual AV conduction’. Br Heart J. 1975;37:1216–27.CrossRefGoogle Scholar
  26. 26.
    Wu D, Denes P, Bauernfeind R, Dhingra RC, Wyndham C, Rosen KM. Effects of atropine on induction and maintenance of atrioventricular nodal reentrant tachycardia. Circulation. 1979;59:779–88.CrossRefGoogle Scholar
  27. 27.
    Lin JL, Stephen Huang SK, Lai LP, Ko WC, Tseng YZ, Lien WP. Clinical and electrophysiologic characteristics and long-term efficacy of slow-pathway catheter ablation in patients with spontaneous node pathways without inducible tachycardia. J Am Coll Cardiol. 1998;31:855–60.CrossRefGoogle Scholar
  28. 28.
    Stellbrink C, Diem B, Schauerte P, Brehmer K, Schuett H, Hanrath P. Differential effects of atropine and isoproterenol on inducibility of atrioventricular nodal reentrant tachycardia. J Interv Card Electrophysiol. 2001;5:463–9.CrossRefGoogle Scholar
  29. 29.
    Ito M. The effects of atropine on atrio-ventricular conduction in patients with Wolff-Parkinson-White syndrome. Studies with His bundle electrogram. Jpn Circ J. 1976;40:1285–300.CrossRefGoogle Scholar
  30. 30.
    Rivarola EW, Hachul D, Wu T, Pisani C, Hardy C, Raimundi F, et al. Targets and end points in cardiac autonomic denervation procedures. Circ Arrhythm Electrophysiol. 2017;10:1–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Calin Siliste
    • 1
  • Roxana-Nicoleta Siliste
    • 2
  1. 1.Cardiology Department, University Emergency HospitalUniversity of Medicine and Pharmacy “Carol Davila”BucharestRomania
  2. 2.Internal Medicine and Cardiology DepartmentColtea Clinical Hospital, University of Medicine and Pharmacy “Carol Davila”BucharestRomania

Personalised recommendations